Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research

被引:5
作者
Penson, David F. [1 ]
Lin, Daniel W. [2 ]
Karsh, Lawrence [3 ]
Quinn, David I. [4 ]
Shevrin, Daniel H. [5 ]
Shore, Neal [6 ]
Symanowski, James T. [7 ]
Brown, Bruce [8 ]
Forer, David [9 ]
Wong, Elaine K. [9 ]
Flanders, Scott C. [8 ]
机构
[1] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Urol Ctr Colorado, Denver, CO USA
[4] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] North Shore Univ Hlth Syst, Evanston, IL USA
[6] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[7] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA
[8] Astellas Pharma Inc, Northbrook, IL USA
[9] Medivation Inc, San Francisco, CA USA
关键词
castration-resistant prostate cancer; health-related quality of life; treatment utilization; QUALITY-OF-LIFE; VALIDATION; THERAPY; INSTRUMENT; HEALTH; SCALE; MEN;
D O I
10.2217/fon-2016-0298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: This study seeks to improve the understanding of treatment patterns and associated health-related quality of life (HRQoL), clinical outcomes and healthcare utilization in US patients with castration-resistant prostate cancer (CRPC). Patients & methods: Treatment Registry for Outcomes in CRPC Patients (TRUMPET) is a US-based, prospective, observational multicenter registry (NCT02380274) involving patients with CRPC and their caregivers. Patients initiating their first active treatment course will be enrolled from urology and medical oncology practices, with data captured up to 4 years. Results: Information on prescribing patterns, HRQoL, clinical outcomes and healthcare utilization will be collected. Conclusion: TRUMPET will enable scientific understanding of disease management in terms of HRQoL, clinical outcomes and healthcare utilization in clinical practice for patients with CRPC.
引用
收藏
页码:2689 / 2699
页数:11
相关论文
共 25 条
[1]  
[Anonymous], 2015, SEER: cancer stat facts: female breast cancer
[2]  
[Anonymous], 2016, AUA QUALITY AQUA REG
[3]  
[Anonymous], PROSTATE CANC
[4]   The estimation of a preference-based measure of health from the SF-12 [J].
Brazier, JE ;
Roberts, J .
MEDICAL CARE, 2004, 42 (09) :851-859
[5]  
Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
[6]  
Cookson M.S., 2015, Castration-resistant prostate cancer: AUA guideline
[7]   Comorbidity severity and long-term mortality in men with early-stage prostate cancer [J].
Daskivich, T. J. ;
Sadetsky, N. ;
Kaplan, S. H. ;
Greenfield, S. ;
Litwin, M. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8]  
Dreicer R, 2014, CAN J UROL, V21, P93
[9]   Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy prostate instrument [J].
Esper, P ;
Mo, F ;
Chodak, G ;
Sinner, M ;
Cella, D ;
Pienta, KJ .
UROLOGY, 1997, 50 (06) :920-928
[10]   Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer [J].
Fletcher, Barbara Swore ;
Paul, Steven M. ;
Dodd, Marylin J. ;
Schumacher, Karen ;
West, Claudia ;
Cooper, Bruce ;
Lee, Kathryn ;
Aouizerat, Bradley ;
Swift, Patrick ;
Wara, William ;
Miaskowski, Christine A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :599-605